Omnicell (OMCL) Reports In-Line Q3 EPS

Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.42, in-line with the analyst estimate of $0.42. Revenue for the quarter came in at $187.1 million versus the consensus estimate of $192.13 million.

GUIDANCE:

Omnicell sees Q4 2017 EPS of $0.49-$0.55, versus the consensus of $0.52.

For earnings history and earnings-related data on Omnicell (OMCL) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results